Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.58 |
| ▸ | PRKCI | P41743 | 1/20 | 0.58 |
| ▸ | NAMPT | P43490 | 5/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14917461 | 0.89 | PRKCI (0.56) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL2771906 | 0.88 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL30505228 | 0.88 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL30339093 | 0.88 | ALDH1A1 (0.70) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL14917439 | 0.85 | ROCK2 (0.66) | ALDH1A1KDM4EPRKCIHTT | |
| SCHEMBL23045333 | 0.81 | KCNMA1 (0.74) | ALDH1A1MEN1KMT2AKDM4ECYP11B2 | |
| SCHEMBL6034144 | 0.81 | SORT1 (0.72) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL13163097 | 0.81 | CYP11B2 (0.63) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL13966172 | 0.81 | CYP11B2 (0.64) | ALDH1A1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL14917450 | 0.80 | CYP11B2 (0.64) | ALDH1A1MEN1KMT2AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | ALDH1A1 1638/4885MEN1 2870/4885KMT2A 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.